Discover the range of academic oncology titles at Springer Nature here.
© [M] Connect world / stock.adobe.com
Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications
This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome also.
© metamorworks / Getty Images / iStock
Radiogenomic biomarkers
For this collection, guest edited by Dr. Jeon-Hor Chen (University of California, Irvine), we cordially invite manuscripts from different disciplines. High quality manuscripts related to disease diagnosis, prediction of treatment response, and assessment of disease risk and outcome are encouraged. Manuscripts outside of these topics which are within the scope of translational research are also welcome.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Articles
-
The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer
-
Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases
-
Roles of IFN-γ in tumor progression and regression: a review
-
Metabolomic analyses for atherosclerosis, diabetes, and obesity
-
Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives
Springer Nature Oncology Portfolio
Editors-in-Chief
Chung-Tsen Hsueh, Loma Linda University
Delong Liu, New York Medical College
Aims and scope
Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines. Read more.
Announcing the launch of In Review
Biomarker Research, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Follow
Annual Journal Metrics
-
Citation Impact
8.633 - 2-year Impact Factor (2021)
7.197 - 5-year Impact Factor (2021)
1.200 - Source Normalized Impact per Paper (SNIP)
1.442 - SCImago Journal Rank (SJR)Speed
6 days to first decision for all manuscripts (Median)
11 days to first decision for reviewed manuscripts only (Median)Usage
823,359 Downloads (2022)
424 Altmetric mentions (2021)
On the blog
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
-
